Literature DB >> 696439

Chemotherapy of malignant gliomas: comparison of the effect of polychemo- and CCNU-therapy.

W D Heiss.   

Abstract

Postoperative survival times of patients suffering from glioblastoma (astrozytoma III-IV) were compared in unselected groups receiving different forms of therapy: standard surgical therapy (16 cases, mean survival time 6.27 +/- 3.75 months), postoperative polychemotherapy (16 patients, survival time 8.96 +/- 4.97 months) or postoperative CCNU-monotherapy (24 cases, survival time 6.98 +/- 4.46 months). The mean survival time in the group receiving polychemotherapy was prolonged significantly when compared to the group with standard treatment. Survival time of the patient group treated with CCNU was not significantly increased. The results indicate that postoperative combination chemotherapy is more effective than CCNU monotherapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 696439     DOI: 10.1007/BF01406637

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  24 in total

1.  Incorporation of thymidine-H3 by cells in normal and injured mouse spinal cord.

Authors:  E K ADRIAN; B E WALKER
Journal:  J Neuropathol Exp Neurol       Date:  1962-10       Impact factor: 3.685

2.  Cell kinetics of human gliomas.

Authors:  T Hoshino; M Barker; C B Wilson; E B Boldrey; D Fewer
Journal:  J Neurosurg       Date:  1972-07       Impact factor: 5.115

3.  Comparison of postoperative irradiation alone and in combination with BCNU (NSC-409962) in the management of malignant gliomas.

Authors:  S A Armentrout; E Foltz; H Vermund; P T Otis
Journal:  Cancer Chemother Rep       Date:  1974 Nov-Dec

4.  Scintiphotographic evaluation of response of brain neoplasms to systemic chemotherapy.

Authors:  S F Handel; M R Powell; C B Wilson; K J Enot
Journal:  J Nucl Med       Date:  1971-06       Impact factor: 10.057

5.  The treatment of glioblastoma multiforme of the brain.

Authors:  R Jelsma; P C Bucy
Journal:  J Neurosurg       Date:  1967-11       Impact factor: 5.115

6.  Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037).

Authors:  H H Hansen; O S Selawry; F M Muggia; M D Walker
Journal:  Cancer Res       Date:  1971-03       Impact factor: 12.701

7.  Chemotherapy of brain tumors. Uptake of tritiated methotrexate by a transplantable intracerebral ependymoblastoma in mice.

Authors:  C H Tator
Journal:  J Neurosurg       Date:  1972-07       Impact factor: 5.115

8.  BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea; NSC-409962) in the treatment of malignant brain tumor--a preliminary report.

Authors:  M D Walker; B S Hurwitz
Journal:  Cancer Chemother Rep       Date:  1970-08

9.  Combination chemotherapy with 1-(2-chloroethyl-3-cyclohexyl-1-nitrosourea) (CCNU), vincristine and methotrexate in primary and metastatic brain tumors--a preliminary report.

Authors:  J Hildebrand; J Brihaye; L Wagenknecht; J Michel; Y Kenis
Journal:  Eur J Cancer       Date:  1973-09       Impact factor: 9.162

10.  Chloroethyl-cyclohexyl-nitrosourea (CCNU) in the treatment of malignant brain tumors.

Authors:  M L Rosenblum; A F Reynolds; K A Smith; B H Rumack; M D Walker
Journal:  J Neurosurg       Date:  1973-09       Impact factor: 5.115

View more
  2 in total

Review 1.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

2.  Combination chemotherapy (COMP protocol) and radiotherapy of anaplastic supratentorial gliomas.

Authors:  K Jellinger; P Kothbauer; D Volc; R Vollmer; R Weiss
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.